

Mark M Smits

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1550683/mark-m-smits-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65 papers	2,309 citations	23 h-index	47 g-index
67 ext. papers	2,862 ext. citations	7.9 avg, IF	5.18 L-index

#	Paper	IF	Citations
65	Kidney hemodynamic profile and systemic vascular function in adults with type 2 diabetes: Analysis of three clinical trials.. <i>Journal of Diabetes and Its Complications</i> , 2022 , 36, 108127	3.2	0
64	Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2022 , 24, 115-124	6.7	1
63	Whole-body insulin clearance in people with type 2 diabetes and normal kidney function: Relationship with glomerular filtration rate, renal plasma flow, and insulin sensitivity.. <i>Journal of Diabetes and Its Complications</i> , 2022 , 36, 108166	3.2	
62	Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 63	8.7	2
61	The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. <i>Scientific Reports</i> , 2021 , 11, 10624	4.9	3
60	Skin microvascular function and renal hemodynamics in overweight patients with type 2 diabetes: A cross-sectional study. <i>Microcirculation</i> , 2021 , 28, e12700	2.9	1
59	Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function. <i>American Journal of Physiology - Renal Physiology</i> , 2021 , 320, F1152-F1158	4.3	0
58	Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands. <i>Journal of Diabetes and Metabolic Disorders</i> , 2021 , 1-6	2.5	4
57	Safety of Semaglutide. <i>Frontiers in Endocrinology</i> , 2021 , 12, 645563	5.7	7
56	Liraglutide and sitagliptin have no effect on intestinal microbiota composition: A 12-week randomized placebo-controlled trial in adults with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2021 , 47, 101223	5.4	5
55	Herpes zoster after COVID vaccination. <i>International Journal of Infectious Diseases</i> , 2021 , 111, 169-171	10.5	16
54	Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1847-1856	6.7	4
53	Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. <i>Cardiovascular Research</i> , 2020 , 116, 916-930	9.9	33
52	High Prevalence of Intraductal Papillary Mucinous Neoplasms in Type 2 Diabetes Mellitus Patients. <i>Pancreas</i> , 2020 , 49, e5-e7	2.6	1
51	Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. <i>Journal of Hypertension</i> , 2020 , 38, 1811-1819	1.9	7
50	Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial. <i>Diabetes Care</i> , 2020 , 43, 2889-2893	14.6	6
49	Renal sinus fat and renal hemodynamics: a cross-sectional analysis. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2020 , 33, 73-80	2.8	15

48	The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. <i>Kidney International</i> , 2020 , 97, 202-212	9.9	117
47	Plasma uric acid and renal haemodynamics in type 2 diabetes patients. <i>Nephrology</i> , 2020 , 25, 290-297	2.2	
46	Assessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearance. <i>Microcirculation</i> , 2019 , 26, e12580	2.9	5
45	GLP-1 receptor agonists do not affect sodium intake: Exploratory analyses from two randomized clinical trials. <i>Nutrition</i> , 2019 , 67-68, 110524	4.8	1
44	Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, F231-F240	4.3	14
43	Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1235-1245	6.7	19
42	Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients. <i>Hypertension</i> , 2018 , 72, 314-322	8.5	6
41	Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes. <i>Diabetic Medicine</i> , 2017 , 34, 591-592	3.5	3
40	The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. <i>Diabetes Research and Clinical Practice</i> , 2017 , 124, 1-10	7.4	13
39	Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. <i>Journal of the American Society of Nephrology: JASN</i> , 2017 , 28, 1023-1039	12.7	303
38	Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study. <i>Scandinavian Journal of Gastroenterology</i> , 2017 , 52, 881-885	2.4	5
37	Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-largine: An 8-week, randomised, open-label trial. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1669-1680	6.7	37
36	Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. <i>Diabetes Care</i> , 2017 , 40, 301-308	14.6	11
35	GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. <i>Nature Reviews Nephrology</i> , 2017 , 13, 605-628	14.9	154
34	Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients. <i>Pancreas</i> , 2017 , 46, e75-e76	2.6	3
33	Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial. <i>European Journal of Endocrinology</i> , 2017 , 176, 77-86	6.5	27
32	Exenatide improves β -cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial. <i>European Journal of Endocrinology</i> , 2016 , 175, 345-52	6.5	22
31	GLP-1-Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016 , 36, 2125-32	9.4	21

30	Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial. <i>Diabetologia</i> , 2016 , 59, 2588-2593	10.3	74
29	Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 893-902	18.1	204
28	Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 281-8	6.7	5
27	Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 178-85	6.7	57
26	Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 116-8	2.2	15
25	GLP-1 based therapies: clinical implications for gastroenterologists. <i>Gut</i> , 2016 , 65, 702-11	19.2	30
24	Effect of 3 Years of Treatment With Exenatide on Postprandial Glucagon Levels. <i>Diabetes Care</i> , 2016 , 39, e42-3	14.6	9
23	Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males. <i>British Journal of Clinical Pharmacology</i> , 2016 , 81, 613-20	3.8	44
22	Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 224-35	6.7	40
21	Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. <i>Diabetologia</i> , 2016 , 59, 1412-1421	10.3	74
20	Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Diabetes Care</i> , 2016 , 39, 2042-2050	14.6	66
19	Renoprotection in LEADER and EMPA-REG OUTCOME. <i>Lancet Diabetes and Endocrinology</i> , 2016 , 4, 812-4	18.1	9
18	Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 1217-1225	6.7	30
17	Incretin-based drugs and renoprotection-is hyperfiltration key?. <i>Kidney International</i> , 2015 , 87, 660-1	9.9	9
16	GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1538-43	9.4	20
15	Pleiotropic effects of type 2 diabetes management strategies on renal risk factors. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 367-81	18.1	63
14	Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. <i>BMJ Open</i> , 2015 , 5, e009579	3	28
13	Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. <i>Diabetes Care</i> 2015;38:1089-1098. <i>Diabetes Care</i> , 2015 , 38, e106-7	14.6	1

12	Understanding EMPA-REG OUTCOME. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 928-9	18.1	57
11	The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?. <i>Nature Reviews Nephrology</i> , 2014 , 10, 88-103	14.9	127
10	Combining incretin-based drugs and RAAS inhibitors: more cons than pros?. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 684-5	18.1	11
9	Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase. <i>Diabetes Research and Clinical Practice</i> , 2014 , 106, 617-26	7.4	6
8	Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. <i>Annals of Epidemiology</i> , 2013 , 23, 415-21	6.4	14
7	Advances in pharmacologic therapies for type 2 diabetes. <i>Current Atherosclerosis Reports</i> , 2013 , 15, 302	6	13
6	Non-alcoholic fatty liver disease as an independent manifestation of the metabolic syndrome: results of a US national survey in three ethnic groups. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013 , 28, 664-70	4	103
5	PS9 - 1. Postprandial Haemodynamic Responses Are Altered in Uncomplicated Type 2 Diabetes. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2013 , 11, 157-157	0	
4	Arm length is associated with type 2 diabetes mellitus in Japanese-Americans. <i>Diabetologia</i> , 2012 , 55, 1679-84	10.3	8
3	The clinical significance of pancreatic steatosis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011 , 8, 169-77	24.2	165
2	Smoking is related to pancreatic fibrosis in humans. <i>American Journal of Gastroenterology</i> , 2011 , 106, 1161-6; quiz 1167	0.7	50
1	Nonalcoholic fatty liver disease is related to nonalcoholic fatty pancreas disease. <i>Pancreas</i> , 2010 , 39, 1185-90	2.6	111